Litcius/Paper detail

Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified

Koen Debackere, Lukas Marcelis, Sofie Demeyer, Marlies Vanden Bempt, Nicole Mentens, Olga Gielen, Kris Jacobs, Michaël Broux, Gregor Verhoef, Lucienne Michaux, Carlos Graux, Iwona Włodarska, Philippe Gaulard, Laurence de Leval, Thomas Tousseyn, Jan Cools, Daan Dierickx

2021Nature Communications36 citationsDOIOpen Access PDF

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas with poor prognosis. Up to 30% of PTCL lack distinctive features and are classified as PTCL, not otherwise specified (PTCL-NOS). To further improve our understanding of the genetic landscape and biology of PTCL-NOS, we perform RNA-sequencing of 18 cases and validate results in an independent cohort of 37 PTCL cases. We identify FYN-TRAF3IP2, KHDRBS1-LCK and SIN3A-FOXO1 as new in-frame fusion transcripts, with FYN-TRAF3IP2 as a recurrent fusion detected in 8 of 55 cases. Using ex vivo and in vivo experiments, we demonstrate that FYN-TRAF3IP2 and KHDRBS1-LCK activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinically available drugs.

Topics & Concepts

FYNPeripheral T-cell lymphomaLymphomaT cellCancer researchBiologyT-cell lymphomaIn vivoT-cell receptorSignal transductionCell biologyGeneticsImmunologyTyrosine kinaseImmune systemT-cell and Retrovirus StudiesLymphoma Diagnosis and TreatmentUbiquitin and proteasome pathways
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified | Litcius